Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 78

1.

Omalizumab in children.

Licari A, Marseglia A, Caimmi S, Castagnoli R, Foiadelli T, Barberi S, Marseglia GL.

Paediatr Drugs. 2014 Dec;16(6):491-502. doi: 10.1007/s40272-014-0107-z.

2.

Omalizumab in asthma: an update on recent developments.

Humbert M, Busse W, Hanania NA, Lowe PJ, Canvin J, Erpenbeck VJ, Holgate S.

J Allergy Clin Immunol Pract. 2014 Sep-Oct;2(5):525-36.e1. doi: 10.1016/j.jaip.2014.03.010. Epub 2014 Jun 11.

PMID:
25213045
3.

Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review.

D'Amato G, Stanziola A, Sanduzzi A, Liccardi G, Salzillo A, Vitale C, Molino A, Vatrella A, D'Amato M.

Multidiscip Respir Med. 2014 Apr 15;9(1):23. doi: 10.1186/2049-6958-9-23. eCollection 2014. Review.

4.

Effectiveness of omalizumab in a patient with a life-threatening episode of bronchospasm and larynx angioedema after exposure to house dust.

Kupryś-Lipińska I, Korczyńska P, Tworek D, Kuna P.

Postepy Dermatol Alergol. 2014 Feb;31(1):39-44. doi: 10.5114/pdia.2014.40659. Epub 2014 Feb 25.

5.

Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table.

Kornmann O, Watz H, Fuhr R, Krug N, Erpenbeck VJ, Kaiser G.

Pulm Pharmacol Ther. 2014 Aug;28(2):149-53. doi: 10.1016/j.pupt.2014.03.003. Epub 2014 Mar 18.

6.

Current status of therapy with omalizumab in children.

Baena-Cagnani CE, Gómez RM.

Curr Opin Allergy Clin Immunol. 2014 Apr;14(2):149-54. doi: 10.1097/ACI.0000000000000044. Review.

PMID:
24535142
7.

Omalizumab, an anti-immunoglobulin E antibody: state of the art.

Incorvaia C, Mauro M, Russello M, Formigoni C, Riario-Sforza GG, Ridolo E.

Drug Des Devel Ther. 2014 Feb 7;8:197-207. doi: 10.2147/DDDT.S49409. eCollection 2014.

8.

Omalizumab for asthma in adults and children.

Normansell R, Walker S, Milan SJ, Walters EH, Nair P.

Cochrane Database Syst Rev. 2014 Jan 13;1:CD003559. doi: 10.1002/14651858.CD003559.pub4. Review.

PMID:
24414989
9.

Anti-IgE therapy to Kimura's disease: a pilot study.

Nonaka M, Sakitani E, Yoshihara T.

Auris Nasus Larynx. 2014 Aug;41(4):384-8. doi: 10.1016/j.anl.2013.12.006. Epub 2014 Jan 7.

PMID:
24406057
10.

Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.

Somerville L, Bardelas J, Viegas A, D'Andrea P, Blogg M, Peachey G.

Curr Med Res Opin. 2014 Jan;30(1):59-66. doi: 10.1185/03007995.2013.844115. Epub 2013 Oct 1.

PMID:
24028677
11.

Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation.

Macglashan DW Jr, Saini SS.

J Allergy Clin Immunol. 2013 Oct;132(4):906-11.e1-4. doi: 10.1016/j.jaci.2013.04.056. Epub 2013 Jun 20.

12.

Omalizumab and hypersensitivity reactions.

Shankar T, Petrov AA.

Curr Opin Allergy Clin Immunol. 2013 Feb;13(1):19-24. doi: 10.1097/ACI.0b013e32835bf3f5. Review.

PMID:
23242113
13.

Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands.

van Nooten F, Stern S, Braunstahl GJ, Thompson C, Groot M, Brown RE.

J Med Econ. 2013;16(3):342-8. doi: 10.3111/13696998.2012.756398. Epub 2012 Dec 18.

PMID:
23216016
14.

Omalizumab: clinical use for the management of asthma.

Thomson NC, Chaudhuri R.

Clin Med Insights Circ Respir Pulm Med. 2012;6:27-40. doi: 10.4137/CCRPM.S7793. Epub 2012 Jun 12.

15.

Omalizumab inhibits acceleration of FcεRI-mediated responsiveness of immature human mast cells by immunoglobulin E.

Okayama Y, Kashiwakura J, Sasaki-Sakamoto T, Matsumoto K, Hashimoto N, Ohmori K, Kawakami T, Saito H, Ra C.

Ann Allergy Asthma Immunol. 2012 Mar;108(3):188-94. doi: 10.1016/j.anai.2012.01.009.

PMID:
22374203
16.

Omalizumab beyond asthma.

Sanchez J, Ramirez R, Diez S, Sus S, Echenique A, Olivares M, Cardona R.

Allergol Immunopathol (Madr). 2012 Sep-Oct;40(5):306-15. doi: 10.1016/j.aller.2011.09.011. Epub 2012 Jan 20. Review.

PMID:
22264640
17.

Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.

Siergiejko Z, Świebocka E, Smith N, Peckitt C, Leo J, Peachey G, Maykut R.

Curr Med Res Opin. 2011 Nov;27(11):2223-8. doi: 10.1185/03007995.2011.620950. Epub 2011 Sep 21.

PMID:
21933100
18.

Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.

Shimizu Y, Dobashi K, Fueki N, Fueki M, Okada T, Tomioka S, Makino S, Mori M.

J Biol Regul Homeost Agents. 2011 Apr-Jun;25(2):177-86.

PMID:
21880206
19.

Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.

Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, Brehler R, Grabbe J, Hunzelmann N, Jakob T, Jung A, Kleine-Tebbe J, Mempel M, Meurer M, Reich K, Ruëff F, Schäkel K, Sengupta K, Sieder C, Simon JC, Wedi B, Zuberbier T, Mahler V, Staubach P.

J Allergy Clin Immunol. 2011 Jul;128(1):202-209.e5. doi: 10.1016/j.jaci.2011.04.038. Epub 2011 Jun 2.

PMID:
21636116
20.

Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.

Lowe PJ, Renard D.

Br J Clin Pharmacol. 2011 Aug;72(2):306-20. doi: 10.1111/j.1365-2125.2011.03962.x.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk